TABLE 4.

Clinical characteristics and treatment outcomes of patients with colistin-resistant A. baumannii infection^a

Variable	Result(s) for patient:
	a	b	c	d	e	f	g	h	i
Age (yr)/gender	61/M	33/M	66/M	51/F	82/M	43/F	51/M	69/F	67/F
Underlying disease	CBD cancer	LT	Hepatocellular carcinoma	Fulminant hepatitis due to HBV flare-up	Colon cancer, pelvic abscess	Myelodysplastic syndrome on BMT	LT	Metastatic CBD cancer	Supraglottic cancer
Acquisition	Hospital onset	Hospital onset	Hospital onset	Hospital onset	Hospital onset	Hospital onset	Hospital onset	Hospital onset	Hospital onset
Ward	SICU	SICU	SICU	MICU	SICU	BMT unit	LT unit	General ward	MICU
Type of infection	VAP, bacteremia	cIAI, bacteremia	cIAI, bacteremia	HAP, bacteremia	HAP, bacteremia	primary bacteremia	primary bacteremia	HAP, bacteremia	VAP
Clinical status
Previous use of colistin	Yes	Yes	No	No	No	No	No	Yes	Yes
Previous use of carbapenem	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Recent operation	Yes	Yes	Yes	No	Yes	No	Yes	No	Yes
Antibiotic therapy	Colistin, vancomycin, amikacin	Colistin, meropenem, vancomycin	Colistin, vancomycin	Meropenem, vancomycin, levofloxacin	Meropenem, vancomycin, metronidazole	Imipenem, vancomycin, levofloxacin	Linezolid, levofloxacin	Tigecycline	Tigecycline, teicoplanin, rifampin, ampicillin-sulbactam
Microbiological eradication	Yes	No	Yes	No	No	No	Yes	No	No
Mortality
14 day	Yes	No	Yes	Yes	Yes	Yes	No	Yes	No
28 day	Yes	No	Yes	Yes	Yes	Yes	No	Yes	No
In hospital	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	No
Infection related	No	No	No	Yes	Yes	Yes	No	Yes	No

^aAbbreviations: M, male; F, female; CBD, common bile duct; LT, liver transplantation; BMT, bone marrow transplantation; SICU, surgical intensive care unit; MICU, medical intensive care unit; VAP, ventilator-associated pneumonia; cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia.